How Doctors Hospital Cayman is making early cancer detection accessible
Doctors Hospital Cayman is proud to have partnered with biotechnology company Cizzle Bio, Inc., to provide its proprietary CIZ1B lung cancer test and DEX-G2 gastric cancer test for use in the hospital’s clinical laboratory, offering patients earlier and more accurate detection of two of the world’s deadliest cancers.
This collaboration aligns closely with Cizzle Bio’s mission to make early cancer detection more widely accessible and supports the company’s broader strategy of bringing its innovative solutions to international and U.S. markets. The company holds exclusive licensing rights for its groundbreaking CIZ1B biomarker lung cancer test in the United States, Canada, and the Caribbean and a worldwide exclusive license for its leading-edge DEX-G2 biomarker gastric cancer test. Cizzle Bio is advancing both tests toward clinical rollout in the United States, with CIZ1B set to launch in the coming months and DEX-G2 following later this year.
“We are thrilled to partner with Doctors Hospital to bring our biomarker blood tests to patients in the Caribbean,” said Bill Behnke, founder and CEO of Cizzle Bio. “This agreement reinforces our commitment to transforming cancer detection with simple, accurate, and cost-effective tools that detect cancer earlier, when it’s most treatable, and improve outcomes for patients worldwide.”
Developed from more than three decades of research at the University of York, the CIZ1B biomarker test detects a variant of the CIZ1 protein, called CIZ1B, that is highly associated with early lung cancer. The DEX-G2 test, originating from years of research at the City of Hope Comprehensive Cancer Center, identifies a novel biomarker signature with high specificity for gastric cancer. Both tests are designed to integrate seamlessly into routine preventive care and diagnostic workflows.
“At Doctors Hospital, we are committed to providing our patients with the most advanced and effective tools for early diagnosis and better outcomes,” said David E. Pellow, BSc. Phm, C.P.P., RPh, director of the hospital’s Ancillary and Support Services. “By incorporating Cizzle Bio’s CIZ1B and DEX-G2 biomarker blood tests into our diagnostic offerings, we are strengthening our ability to detect cancer earlier and deliver more proactive, personalized care to our community.”
The tests are expected to enhance the hospital’s current cancer screening programs by enabling minimally invasive, highly accurate detection methods that support more informed clinical decision-making and improved patient outcomes.
About Cizzle Bio, Inc.
Cizzle Bio is a Texas-based biotechnology company dedicated to revolutionizing cancer diagnostics by pioneering biomarker-based blood tests, starting with early detection of lung and gastric cancer. Our goal is to empower patients, equip clinicians, and improve outcomes through innovation, compassion, and life-saving solutions. We hold exclusive licensing rights for our groundbreaking CIZ1B biomarker test in the United States, Canada, and the Caribbean and a worldwide exclusive license for our DEX-G2 biomarker gastric cancer test. Cizzle Bio is commercializing both tests for U.S. clinical environments, with CIZ1B set to launch in the coming months and DEX-G2 following later this year.
www.cizzlebio.com
Read the full press release here
